New hope for advanced breast cancer: combo therapy targets drug resistance
NCT ID NCT07117630
First seen Dec 10, 2025 · Last updated Jun 14, 2026 · Updated 27 times
Summary
This study tests whether adding two amino acid-based drugs (L-Ornithine L-Aspartate and N-Acetylcysteine) to standard hormone therapy can shrink tumors or slow disease in people with HR+/HER2- advanced breast cancer. About 40 women whose cancer progressed on prior treatments will receive the combination. The goal is to see if the new mix improves response rates and controls the disease longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.